Leap Therapeutics Inc

NASDAQ:LPTXUnited States

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Contact Information

Headquarters

47 Thorndike St Ste B1-1CAMBRIDGE, MA, United States 02141-1799

Phone

617-252-4343

Fax

302-636-5454

Executives

Chairman of the Board

Christopher Mirabelli

President, Chief Executive Officer, Director

Douglas Onsi

Chief Operating Officer

Augustine Lawlor

Chief Scientific Officer

Jason Baum

Vice President, Head - Regulatory Affairs and Quality

Christine Granfield